Abstract Details

Title PatientsLikeMe® Epilepsy Community: Factors Affecting Quality of Life

Topic Epilepsy

Presentation(s) P03 - (-)

Poster/Presentation
Number 122

Objective

Background BACKGROUND: The PatientsLikeMe Epilepsy Community is a free online platform developed in partnership with UCB (launched January 2010) that allows patients to record, monitor and share socio-demographic and clinical characteristics and complete standardized questionnaires measuring HRQoL and mood.

Design/Methods DESIGN/METHODS: Cross-sectional analyses of patient-reported outcomes. Multivariate logistic regressions were performed to identify variables associated with poor HRQoL (< Quartile 1 of Quality of Life in Epilepsy [QOLIE-31/P] total score).

Results RESULTS: By November 2011, 1121 patients (mean age 37.8 years; 72.2% female; mean epilepsy duration 17.8 years) who recorded a diagnosis of epilepsy and multiple seizures had completed the QOLIE-31/P. The median (Q1-Q3) QOLIE-31/P total score was 50.9 (37.3-65.4). Multivariate logistic regression indicated that poor HRQoL was more likely in patients reporting (Odds Ratio [95% confidence interval]): i) moderate/severe problems concentrating (2.96 [1.91-4.59], depression (2.53 [1.75-3.66]), memory problems (2.14 [1.39-3.30]), anxiety (1.62 [1.12-2.35]), fatigue (1.60 [1.05-2.44]); ii) moderate/severe side effects (2.11 [1.25-3.59]); iii) ?1 seizure during the 4 weeks preceding QOLIE-31/P completion (?1 tonic-clonic seizure 2.87 [1.65-4.99]; ?1 non-tonic-clonic seizure 1.61 [1.07-2.42]); iv) shorter epilepsy duration (?1 year 2.51 [1.41-4.45]; >1-10 years 1.71 [1.15-2.53]; both vs >10 years). Patients on newer antiepileptic drugs (AEDs) as monotherapy (0.32 [0.13-0.80]) or polytherapy (0.24 [0.10-0.61]) were less likely to report poor HRQoL than patients on polytherapy with older AEDs, as were patients not reporting AED treatment (0.26 [0.08-0.80]).

Conclusions CONCLUSIONS: The most predictive factors of poor HRQoL were moderate/severe problems concentrating, depression, memory problems, and side effects; occurrence of tonic-clonic seizures and epilepsy duration ?1 year. These results suggest that a holistic approach beyond seizure control should be considered when treating people with epilepsy.

Authors/Disclosures
Simon Borghs PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Tracy Durgin, PharmD (Eisai)	No disclosure on file
Stephen D. Silberstein, MD, FAAN	Dr. Silberstein has received publishing royalties from a publication relating to health care.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Paul Wicks, PhD	No disclosure on file

��ɫ��

��ɫ��